Skipped wells and scientific error during fosfomycin agar dilution and broth microdilution lead to inconsistent minimal inhibitory concentrations and may be cause for reevaluating testing methods for Klebsiella pneumoniae .
Autor: | Bixby ML; University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA., Daley EC; University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA., Collins LB; University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA., Salay JM; University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA., Bryson AL; Virginia Commonwealth University Health System, Richmond, Virginia, USA., Hirsch EB; University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Microbiology spectrum [Microbiol Spectr] 2024 Aug 06; Vol. 12 (8), pp. e0420523. Date of Electronic Publication: 2024 Jun 28. |
DOI: | 10.1128/spectrum.04205-23 |
Abstrakt: | Despite the first-line recommendation of fosfomycin for uncomplicated urinary tract infections (UTIs), there are pressing barriers for optimizing its use for the treatment of non- Escherichia coli Enterobacterales UTI. There are no approved breakpoints for oral use against other Enterobacterales, and the recommended agar dilution (AD) reference method for minimal inhibitory concentration (MIC) determination is largely impractical. Using 160 clinical Klebsiella pneumoniae isolates, we sought to understand rates of skipped wells and MIC imprecision in broth microdilution (BMD) and how that compares to rates of error using AD. Though the Clinical and Laboratory Standards Institute refers to the skipped well phenomena in their recommendation against the use of BMD, there is a paucity of data on its frequency. While AD and BMD produced similar MIC Competing Interests: E.B.H. has received advisory board honoraria from GSK. All other authors declare no relevant conflicts of interest. |
Databáze: | MEDLINE |
Externí odkaz: |